On Tuesday, April 28, FDA finalized three “guidances to the industry” that describe FDA’s standards for approving biosimilar products (biosimilars). A biosimilar is a biological product approved by the FDA based on a showing that (1) it is highly similar to an FDA-approved biological product (reference product), and (2) has no clinically meaningful differences in … Continue reading